Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Healthcare Biotechnology Medical Instruments & Supplies
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > Reminder...
View:
Post by mercedesman on Dec 10, 2021 4:56pm

Reminder...

https://www.estor.it/en/endotoxemia-critically-ill-covid-19-patients-from-pathophysiology-to-advanced-targeted-complementary-therapies/


TAKE HOME MESSAGES

 

  • Critically ill COVID-19 patients present a dysregulated host response to infection
  • Gut dysbiosis is associated with bacteremia (often of Gram-negative origin) and translocation of bacterial products
  • Endotoxemia is common in critically ill COVID-19 patients and correlates with a worse outcome
  • Polymyxin B hemoperfusion can be used as complementary therapy in critically ill COVID-19 patients with endotoxic shock
  • Published data show an improvement in hemodynamics, organ function and reduction in EA, lactate, PCT and CRP levels
Comment by Domino55 on Dec 10, 2021 8:31pm
If you believe what was said in the recent presentation Covid is not much more than a nuisance that has caused trial delays. There was something mumbled/mentioned dismissively about Covid treatment under compassionate care but that was about it. Any talk of PMX treating Covid patients was hype and we know that they can't hype.
Spectral Medical Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities